EVOLVE 104 ADC
Alternative Names: EVOLVE 104 antibody-drug conjugate; EVOLVE-104 ADCLatest Information Update: 21 Jul 2022
At a glance
- Originator EvolveImmune Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 13 Jul 2022 Early research in Solid tumours in USA (unspecified route) prior to July 2022 (EvolveImmune Therapeutics pipeline, July 2022)